Humanwell Healthcare (Group)Ltd Dirección

Dirección controles de criterios 4/4

El CEO de Humanwell Healthcare (Group)Ltd's es Xiafei Deng, nombrado en Jun 2020, tiene una permanencia de 3.83 años. posee directamente un 0.098% de las acciones de la empresa, con un valor de CN¥32.04M. La antigüedad media del equipo directivo y de la junta directiva es de 4 años y 8.5 años, respectivamente.

Información clave

Xiafei Deng

Chief Executive Officer (CEO)

CN¥1.4m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	3.9yrs
Participación del CEO	0.1%
Permanencia media de la dirección	4.1yrs
Promedio de permanencia en la Junta Directiva	8.5yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Xiafei Deng (59 yo)

3.9yrs

Permanencia

CN¥1,370,300

Compensación

Mr. Xiafei Deng serves as President at Humanwell Healthcare (Group) Co.,Ltd. since June 2020. He serves as Director of Wuhan Humanwell Healthcare (Group) Co.,Ltd.and served as its Vice President until Jun...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Xiafei Deng	President & Director	3.9yrs	CN¥1.37m	0.098% CN¥ 32.2m
Yajun Wu	CFO & VP	20.2yrs	CN¥1.01m	0.059% CN¥ 19.6m
Qianlun Li	VP & Secretary	11yrs	CN¥926.50k	0.019% CN¥ 6.1m
Wentao Du	Vice President	20.6yrs	CN¥1.30m	0.056% CN¥ 18.3m
Lie Li	Vice President	4.1yrs	CN¥1.21m	0.032% CN¥ 10.5m
Hongjie Zhang	Vice President	no data	CN¥1.18m	0.028% CN¥ 9.2m
Qiang Yin	Vice President	4.1yrs	CN¥912.00k	0.028% CN¥ 9.2m
Qun Yu	Vice President	3.6yrs	CN¥1.22m	0.028% CN¥ 9.2m

4.1yrs

Permanencia media

53.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 600079 se considera experimentado (4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Xiafei Deng	President & Director	25.3yrs	CN¥1.37m	0.098% CN¥ 32.2m
Min Qi	Supervisor	10yrs	sin datos	sin datos
Rui Zhou	Independent Director	3yrs	CN¥100.00k	sin datos
Lin Qing Liu	Independent director	4yrs	CN¥100.00k	sin datos
Xiao Dong Zhang	Director	27.3yrs	CN¥882.00k	0.029% CN¥ 9.4m
Xuehai Wang	Director	21yrs	CN¥180.00k	0.22% CN¥ 73.9m
Jie Li	Chairman of the Board	21yrs	CN¥2.00m	6.06% CN¥ 2.0b
Yue Xin Du	Chairman of the Supervisory Board	19.2yrs	CN¥66.00k	sin datos
Hansheng Zhou	Director	7.1yrs	sin datos	sin datos
Chenggang Zheng	Supervisor	4yrs	sin datos	sin datos
Kong Na	Representative Member of the Supervisory Board	4yrs	sin datos	sin datos
Xia Yuan	Employee Representative Member of the Supervisory Board	4yrs	sin datos	sin datos

8.5yrs

Permanencia media

54yo

Promedio de edad

Junta con experiencia: La junta directiva de 600079 se considera experimentada (8.5 años de antigüedad promedio).

Humanwell Healthcare (Group)Ltd Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Humanwell Healthcare (Group) Co.,Ltd., Annual General Meeting, Apr 25, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

First quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.41 in 1Q 2023)

Full year 2023 earnings: EPS exceeds analyst expectations

Humanwell Healthcare (Group) Co.,Ltd., Annual General Meeting, Apr 25, 2024

Investor sentiment improves as stock rises 17%

Humanwell Healthcare (Group) Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings released: EPS: CN¥0.41 (vs CN¥0.35 in 2Q 2022)

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.27 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.41 (vs CN¥0.23 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Novo Holdings A/S agreed to acquire The Ritedose Corporation from AGIC Capital, Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) and others.

Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.19 in 2Q 2020)

Price target decreased to CN¥33.31

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.10 in 1Q 2020)

Investor sentiment improved over the past week

New 90-day low: CN¥25.74

Investor sentiment deteriorated over the past week

New 90-day low: CN¥27.26

New 90-day low: CN¥30.20

Humanwell Healthcare (Group) Co.,Ltd. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: CN¥30.82

Analysts update estimates

Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) entered into a preliminary letter of intent to acquire an additional 13% stake in YiChang Humanwell Pharmaceutical Co., Ltd from Li Jie, Chen Xiaoqing, and Xu Huabin.

Price target lowered to CN¥10.32

New 90-day high - CN¥38.00

New 90-day high - CN¥36.85

Chongqing Pharmaceutical (Group) Co., Ltd. signed the Sichuan Humanwell Pharmaceutical Co., Ltd. Equity Transfer Contract to acquire 70% stake in Sichuan Humanwell Pharmaceutical Co., Ltd from Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) for approximately CNY 360 million.

Humanwell Healthcare (Group) Co.,Ltd. to Report First Half, 2020 Results on Aug 22, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad